Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain's lead drug candidate GT-02287 for the treatment of Parkinson's disease and other neurodegenerative diseases is currently being evaluated in a Phase 1 clinical trial. With its Magellan drug discovery platform, Gain is transforming drug discovery by integrating Al, physics-based methods and supercomputing power to discover novel allosteric binding sites and potential first-in-class drug candidates from on-demand libraries with 50 billion compounds in less than 3 months.
Gain Therapeutics Inc Share Price USD0.0001
Gain's clinical Parkinson's drug restores motor function in mice
Gain Therapeutics (GANX) Down 25% on Issue of New Common Stock
What Kind Of Investors Own Most Of Gain Therapeutics, Inc. (NASDAQ
Terenzio Ignoni - SVP, Quality & CMC at Gain Therapeutics
Success story interview with Dr. Manolo Bellotto, Gain
Swiss biotech restores motor function in mice with Parkinson's disease
What are the Strengths, Weaknesses, Opportunities and Threats of
Gain Therapeutics (@GainThera) / X
Gain Therapeutics Company Profile: Stock Performance & Earnings
